Search Results | Scholarly Articles, Journals, and E-Books

Results: 14

Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 575, doi. 10.1007/s10637-024-01472-w
By:
- Peng, Liping;
- Wu, Zhaoquan;
- Sun, Wei;
- Wang, Chunjiang
Publication type:
Article
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 559, doi. 10.1007/s10637-024-01470-y
By:
- Mori, Nami;
- Tamaki, Nobuharu;
- Takaki, Shintaro;
- Tsuji, Keiji;
- Tada, Toshifumi;
- Nakamura, Shinichiro;
- Ochi, Hironori;
- Mashiba, Toshie;
- Doisaki, Masao;
- Marusawa, Hiroyuki;
- Kobashi, Haruhiko;
- Fujii, Hideki;
- Ogawa, Chikara;
- Nonogi, Michiko;
- Arai, Hirotaka;
- Uchida, Yasushi;
- Urawa, Naohito;
- Narita, Ryoichi;
- Akahane, Takehiro;
- Kondo, Masahiko
Publication type:
Article
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 601, doi. 10.1007/s10637-024-01469-5
By:
- De Iuliis, Francesca;
- Taglieri, Ludovica;
- Salerno, Gerardo;
- Giuffrida, Anna;
- Milana, Bernardina;
- Giantulli, Sabrina;
- Carradori, Simone;
- Silvestri, Ida;
- Scarpa, Susanna
Publication type:
Article
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 538, doi. 10.1007/s10637-024-01467-7
By:
- Tachibana, Yusuke;
- Morimoto, Kenji;
- Yamada, Tadaaki;
- Kawachi, Hayato;
- Tamiya, Motohiro;
- Negi, Yoshiki;
- Goto, Yasuhiro;
- Nakao, Akira;
- Shiotsu, Shinsuke;
- Tanimura, Keiko;
- Takeda, Takayuki;
- Okada, Asuka;
- Harada, Taishi;
- Date, Koji;
- Chihara, Yusuke;
- Hasegawa, Isao;
- Tamiya, Nobuyo;
- Katayama, Yuki;
- Nishioka, Naoya;
- Iwasaku, Masahiro
Publication type:
Article
Broad-spectrum anti-cancer activity of fused human arginase variants.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 531, doi. 10.1007/s10637-024-01466-8
By:
- Prasad, Yenisetti Rajendra;
- Anakha, J.;
- Jawalekar, Snehal Sainath;
- Pande, Abhay H.
Publication type:
Article
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer: sitravatinib in advanced RCC and CRPC: Pant et al.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 547, doi. 10.1007/s10637-024-01465-9
By:
- Pant, Shubham;
- Cho, Byoung Chul;
- Kyriakopoulos, Christos E.;
- Spira, Alexander;
- Tannir, Nizar;
- Werner, Theresa L.;
- Yan, Xiaohong;
- Neuteboom, Saskia;
- Chao, Richard;
- Goel, Sanjay
Publication type:
Article
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 510, doi. 10.1007/s10637-024-01464-w
By:
- Wu, Zhaoquan;
- Sun, Wei;
- Wang, Chunjiang
Publication type:
Article
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 566, doi. 10.1007/s10637-024-01463-x
By:
- Heath, Elisabeth I.;
- Chen, Wei;
- Heilbrun, Lance;
- Choi, Jae E.;
- Dobson, Kimberlee;
- Smith, Melanie;
- Maj, Tomasz;
- Vaishampayan, Ulka;
- Kryczek, Ilona;
- Zou, Weiping;
- Chinnaiyan, Arul M.;
- Qiao, Yuanyuan
Publication type:
Article
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 492, doi. 10.1007/s10637-024-01462-y
By:
- Gupta, Pranav;
- Chatterjee, Manash;
- Kim, Yeonil;
- Deschamps, Kathleen;
- Lemoine, Lieselotte;
- Van Dyck, Kristien;
- Matthews, Catherine Zhou;
- Rottey, Sylvie;
- Stoch, Aubrey;
- Lai, Eseng
Publication type:
Article
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 581, doi. 10.1007/s10637-024-01461-z
By:
- Lakhani, Nehal J.;
- Burris III, Howard;
- Miller Jr., Wilson H.;
- Huang, Mo;
- Chen, Lin-Chi;
- Siu, Lillian L.
Publication type:
Article
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 590, doi. 10.1007/s10637-024-01460-0
By:
- Li, Helin;
- Zhang, Wenjing;
- Meng, Qiu;
- Shuai, Qi
Publication type:
Article
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 481, doi. 10.1007/s10637-024-01458-8
By:
- Ghalib, Mohammad H.;
- Pulla, Mariano Provencio;
- De Miguel Luken, Maria J.;
- de Juan, Virginia Calvo;
- Chaudhary, Imran;
- Hammami, M Bakri;
- Vikash, Sindhu;
- Maitra, Radhashree;
- Martinez, Sara;
- Kahatt, Carmen;
- Extremera, Sonia;
- Fudio, Salvador;
- Goel, Sanjay
Publication type:
Article
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 500, doi. 10.1007/s10637-024-01457-9
By:
- Xia, Chunyong;
- Liu, Zhijing;
- Liu, Jie;
- Lin, Li;
- Chen, Maohua
Publication type:
Article
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery.
Published in:
Investigational New Drugs, 2024, v. 42, n. 5, p. 518, doi. 10.1007/s10637-024-01455-x
By:
- Silli, Epiphane K.;
- Zheng, Zhenjiang;
- Zhou, Xintao;
- Li, Mengfei;
- Tang, Jiali;
- Guo, Ruizhe;
- Tan, Chunlu;
- Wang, Ying
Publication type:
Article